Double Blind, Placebo Controlled Study Assessing the Efficacy of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Patients With Platinum Pre-treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Latest Information Update: 08 Dec 2023
At a glance
- Drugs Buparlisib (Primary) ; Paclitaxel
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms BERIL-1
- Sponsors Novartis Pharmaceuticals
- 24 Oct 2023 Results (n=145) assessing a novel methodology to identify subjects that could derive benefit from Buparlisib treatment in metastatic SCCHN patients. The analysis was focused on image analysis of H&E images to select features associated with improved clinical benefit from paclitaxel+buparlisib presented at the 48th European Society for Medical Oncology Congress
- 06 Jun 2023 Results evaluating hierarchically prognostic and predictive biomarkers to select predefined analysis in the current Phase 3 clinical trial, BURAN (NCT04338399) post immune modulatory therapy, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 30 Jul 2018 According to an Adlai Nortye media release, results from this study were published in the Clinical Cancer Research, June 2018.